Share

US-based pharmaceutical firm Ischemix has enrolled the first patient in a Phase IIa trial of its lead compound CMX-2043 to prevent contrast-induced acute kidney injury (CI-AKI) in acute coronary syndrome patients undergoing coronary angiography (the CARIN trial).

CMX-2043 is a chemically-modified, naturally-occurring molecule with an excellent safety profile that has showed efficacy in a prior human clinical trial.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Brigham and Women’s Hospital Heart & Vascular Center Interventional Cardiovascular Programs executive director and CARIN trial lead investigator Deepak Bhatt said: "The CARIN trial presents an exciting opportunity to study the potential of CMX-2043 to treat cardiac patients who are at serious risk of complications."

"The CARIN trial presents an exciting opportunity to study the potential of CMX-2043 to treat cardiac patients who are at serious risk of complications."

Around 240 patients will be enrolled in the CARIN trial, which will evaluate the ability of CMX-2043 to prevent CI-AKI.

In the US, approximately 500,000 coronary angiography patients are at high-risk of developing CI-AKI and currently there are no approved drug therapies for the same.

See Also:

The trial will also seek to confirm the results of its prior Phase IIa trial, where CMX-2043 prevented peri-procedural cardiac injury in patients undergoing a percutaneous coronary intervention (PCI).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ischemix intends to announce data from the CARIN trial in mid-2015, when it plans to initiate discussions with prospective corporate partners.

The company believes that CMX-2043 has the opportunity to address indications with in excess of a billion dollars of potential revenues, while producing a net cost savings to the health care system.